ESR1 and breast cancer: Both raloxifene and 4-hydroxytamoxifen are two antiestrogens that are also AhR ligands that inhibit apoptosis and differentiation of breast cancer cells [117,118] and they are part of a group of compounds that are dual AhR-ER and ligands.